Last $26.30 USD
Change Today -0.03 / -0.11%
Volume 331.4K
IMS On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

ims health holdings inc (IMS) Key Developments

IMS Health Holdings, Inc. Announces Executive Changes, January 1, 2015

IMS Health Holdings, Inc. announced Paul Thomson will be resigning from his current position as Senior Vice President, Human Resources & Administration, effective January 1, 2015. He will be succeeded by Clinton Wolfe who is appointed Vice President, Human Resources, effective January 1, 2015.

IMS Health Names Mason Tenaglia as Vice President, Payer & Managed Care Insights, IMS Institute for Healthcare Informatics

IMS Health announced that Mason Tenaglia has been appointed as vice president, Payer & Managed Care Insights, IMS Institute for Healthcare Informatics, a new position. In this role, Tenaglia is responsible for advancing the company's payer and managed care thought leadership, as well as engaging with key leaders in the healthcare industry, academia and government.

IMS Health Holdings, Inc. Presents at Barclays Capital Global Technology Conference, Dec-09-2014 11:00 AM

IMS Health Holdings, Inc. Presents at Barclays Capital Global Technology Conference, Dec-09-2014 11:00 AM. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, California, United States. Speakers: Ronald E. Bruehlman, Chief Financial Officer and Senior Vice President.

IMS Health Holdings, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 11:30 AM

IMS Health Holdings, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 11:30 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Ronald E. Bruehlman, Chief Financial Officer and Senior Vice President.

IMS Health Holdings, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014

IMS Health Holdings, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s revenue increased 5.4% on a constant currency basis, or 3.7% on a reported basis, to $656 million, compared with $633 million in the third quarter of 2013. The company's strong revenue performance in the third quarter was driven by a 10.8% increase in technology services revenue on a constant currency basis, or 9.3% on a reported basis. Information offerings revenue was up 1.8% on a constant currency basis, or flat on a reported basis. Adjusted EBITDA increased 10.5% on a constant currency basis, or 6.1% reported to $221 million, compared with $209 million in the third quarter of 2013. Net income was $47 million, compared with a net loss of $20 million in last year's third quarter. Reported adjusted net income was $125 million, down $9 million from $134 million in the prior year's quarter, as the benefit of Adjusted EBITDA growth and lower interest expense was more than offset by a $47 million tax refund received in 2013. Diluted earnings per share was $0.14 compared with a loss of $0.07 per share in the third quarter of 2013. Adjusted diluted earnings per share was $0.37 compared with $0.47 in the prior-year period. Excluding the impact of last year's $47 million tax refund, adjusted diluted earnings per share would have increased $0.07 per share compared with the prior-year quarter. The company reported operating income of $93 million compared to $100 million, income before income taxes of $58 million compared to loss before income taxes of $40 million, net cash provided by operating activities of $191 million compared to $212 million, capital expenditures of $14 million compared to $8 million, additions to computer software of $26 million compared to $22 million and free cash flow of $151 million compared to $182 million for the last year. For the nine months, the company’s revenue increased 5.8% on a constant currency basis, or 5.0% to $1,963 million on a reported basis, compared to $1,870 million in the same period last year. Adjusted EBITDA increased 9.8% on a constant currency basis, or 7.5% to $664 million on a reported basis, compared with $618 million in the first nine months of 2013. The year-to-date net loss was $197 million or $0.63 per diluted share, compared with breakeven results in the prior-year period, with the decline due to one-time IPO-related charges. Adjusted net income was $329 million or $1.02 per diluted share, up $23 million from $306 million or $1.06 per diluted share in the prior-year period. The company reported operating income of $121 million compared to $276 million, loss before income taxes of $338 million compared to $6 million, net cash used in operating activities of $37 million compared to net cash provided by operating activities of $336 million, capital expenditures of $59 million compared to $25 million, additions to computer software of $70 million compared to 53 million and free cash out flow of $166 million compared to free cash flow of $258 million for the last year. Net debt was $3.6 billion. Consistent with previous guidance, on a constant currency basis, IMS Health now expects revenue growth of 5.5% to 5.7%, adjusted EBITDA growth of 9.0% to 9.8% against previous guidance of 5% to 6% revenue growth and 7.5% to 9% adjusted EBITDA growth and adjusted net income growth of 20% to 21%. As a result of the headwind created by the broad strengthening of the USD against foreign currencies, on a reported basis IMS Health now expects revenue growth of 3.8% to 4.0%, Adjusted EBITDA growth of 5.8 to 6.6%, and adjusted diluted earnings per share of $1.34 to $1.36. Unlevered free cash flow is now projected to be 70% to 75% of adjusted EBITDA, excluding the investment for the company's new global delivery center in Bangalore. The company expects full year adjusted diluted earnings per share of $1.40 to $1.42 on a constant currency basis. The full year guidance for adjusted net income growth is now 20% to 21% on a constant currency basis. On a reported basis, including FX, the company narrowing guidance for adjusted net income growth to 15% to 16% and this remains within previously issued guidance range despite the adverse impact of FX.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMS:US $26.30 USD -0.03

IMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $103.73 USD +0.02
Informatica Corp $38.92 USD +0.17
IPSOS €23.70 EUR 0.00
PAREXEL International Corp $56.48 USD +0.57
Teradata Corp $45.22 USD +0.41
View Industry Companies
 

Industry Analysis

IMS

Industry Average

Valuation IMS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 4.5x
Price/Cash Flow 12.5x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMS HEALTH HOLDINGS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.